The prevalence of carbapenem-resistant Enterobacteriaceae (CRE) increased by nearly threefold between 2015 and 2016, due to a broadening definition of the infection.
Previously, the CDC reported a CRE incidence of 2.93 per 100,000 people in 2012 and 2013 in selected sites, but changed the CRE surveillance case definition in 2016 to improve sensitivity for detecting carbapenemase-producing (CP)-CRE. The new definition is an isolate of Escherichia coli, Enterobacter or Klebsiella